Quick read: The cheapest GLP-1 telehealth platforms in 2026 advertise compounded semaglutide starting at $130 to $200 per month at the lowest titration dose. Pricing alone is a poor decision-making tool. The platforms differ on clinical model, pharmacy partnerships, transparency, and side-effect support — and those differences matter more during actual treatment than the headline price does at signup. This comparison covers Oak Longevity, TrimRx, and MEDVi side-by-side and walks through what each is actually best for.
Disclaimer: This article is for informational and educational purposes only. It is not medical advice. GLP-1 medications are prescription drugs. Discuss your full medical history with a licensed healthcare provider before choosing any platform. Compounded medications are not FDA-approved finished drug products. Pricing reflects publicly displayed information as of May 2026 and is subject to change.
Why “Cheapest” Is Only Half the Question
Search results for “cheapest GLP-1” return rankings that focus almost entirely on monthly cost. The framing makes sense for some product categories. For prescription weight-loss medication, it's incomplete.
What actually determines the experience over six to twelve months on a GLP-1 medication: which compounding pharmacy is preparing the medication, what the provider does when you have a side effect, whether dose adjustments are clinically driven or formulaically driven, what happens when you titrate up (and whether the price changes), and what the platform's plan is when regulatory pressure shifts.
None of those variables show up in the headline price. All of them show up in the actual patient experience.
That said, price is not nothing. For uninsured patients paying out of pocket, the difference between $130 per month and $400 per month is substantial. The honest comparison addresses both sides — what each platform charges, and what each platform actually delivers for the price.
Oak Longevity
Headline pricing: Compounded semaglutide from $130 per month. Compounded tirzepatide from $199 per month. $50 off first month with code OAKNEW50. Free shipping. No membership fee.
Clinical model: Online intake, asynchronous provider review, no video call required. Approval typically same-day for eligible patients.
What Oak does well: Aggressive pricing at the entry titration dose. Verifiable customer service responsiveness — multiple independent reviewers describe quick callbacks. Clean intake process. Coverage in all 50 states.
Where I'd want clearer answers: Specific compounding pharmacy disclosure. The platform's clinical response protocol when a patient reports a serious side effect. The pricing trajectory at higher titration doses, which several customer reviews indicate increases meaningfully.
Best fit for: Patients who have already had a clinical conversation about GLP-1 medications, are comfortable with the no-video-call model, value cost transparency and shipping speed, and don't have medical complexity that warrants a more involved clinical relationship.
For the deeper review of Oak specifically, see my Oak Longevity review.
TrimRx
Headline pricing: Compounded semaglutide from $199 per month at the entry dose. Compounded tirzepatide from $349 per month. Promotional pricing has been observed at $140 off plus free shipping during certain windows. All-inclusive pricing — no separate consultation fee.
Clinical model: Telehealth-based with licensed providers. Includes ongoing follow-up care as part of the program structure. Offers oral GLP-1 and oral GLP-1/GIP options alongside injectable formulations, which is unusual in the compounded space.
What TrimRx does well: Transparent communication about the difference between compounded and brand-name medications. Multiple medication form options (injectable and oral). Strong customer base — the platform reports a 4.8 rating across 100,000+ customers, and independent customer reviews describe responsive support and thorough provider consultations.
Where I'd want clearer answers: Like all compounded GLP-1 platforms, the specific pharmacy partner and the long-term sourcing plan post-shortage are worth confirming directly before signup.
Best fit for: Patients who want a more structured program with included follow-up care, patients interested in oral GLP-1 options, and patients willing to pay slightly more for a platform that emphasizes ongoing clinical relationship.
My existing TrimRx review covers the platform in more detail.
MEDVi GLP-1 Compound
Headline pricing: Tiered pricing structure. Compounded options at lower price points, branded medication (where available) at premium pricing. Specific pricing varies by tier and dose.
Clinical model: Structured medical weight loss program. Multiple medication options including compounded semaglutide, compounded tirzepatide, and in some cases branded medications such as Ozempic when clinically appropriate and available. Provider-supervised throughout.
What MEDVi does well: Multiple medication options under one platform. Clear positioning as a medical weight loss program rather than a pure compounded-medication marketplace. Once-weekly injection or daily dissolvable tablet format choices.
Where I'd want clearer answers: The specific structure of clinical follow-up. The interaction between compounded and branded options under their model. Pricing transparency at different tiers.
Best fit for: Patients who want flexibility between compounded and (where available) branded options. Patients who prefer a more structured medical weight loss framework over a pure prescription-fulfillment model.
Side-by-Side Quick Comparison
Oak Longevity: Lowest entry price. No video call. Free shipping. Best fit for self-directed patients with established clinical context.
TrimRx: Higher entry price, more clinical structure, more medication form options (injectable and oral). Best fit for patients wanting structured ongoing care.
MEDVi: Tiered pricing across compounded and branded options. Best fit for patients wanting flexibility between medication classes.
For the broader category context — what compounded actually means and what the 2025 FDA shortage resolution changed — see compounded semaglutide vs Wegovy. For the medication-level decision, see tirzepatide vs semaglutide. For the side-effect questions to ask any platform, see GLP-1 side effects guide.
What the Cheapest Platforms Have in Common
Every low-cost compounded GLP-1 telehealth platform shares a similar economic model. The medication is sourced from a licensed compounding pharmacy, the provider review is conducted asynchronously through an online intake, and overhead is kept lean by avoiding traditional clinic infrastructure.
The platforms that are doing this well in 2026 share a few characteristics:
Verifiable U.S. business operations with working phone numbers and customer service. Public reviews on independent platforms — Trustpilot, BBB, or similar — that include both positive and critical feedback. Transparent disclosure that compounded medications are not FDA-approved as finished products. Clear policies on cancellation, refunds, and what happens if the prescription isn't approved. A medication intake process that screens for the actual contraindications, including thyroid cancer history and pregnancy.
The platforms operating without these signals — international shipping addresses, no public phone number, vague language about compounding pharmacy, no contraindication screening, automatic approval without provider review — are different. Cost should not be the deciding factor on a platform like that.
What to Verify Before Signing Up With Any Platform
The questions worth asking, regardless of which platform you're considering:
Which compounding pharmacy fills the prescription, and what is its 503A or 503B status. A platform that won't tell you specifically is meaningfully different from one that does.
What does the provider review consist of. An asynchronous review of an intake form is one thing. An automated approval flow with a provider stamp at the end is another. The difference is hard to verify from outside, but customer reviews often surface it.
What happens if I report a side effect. What is the response time, and what is the clinical pathway. Side-effect support is where the cheap-vs-quality difference shows up most clearly.
What is the dose-titration pricing trajectory. The headline price is usually for the lowest dose. What does the third or fourth dose tier cost.
What is the cancellation and refund policy. Specifically: what happens if the prescription is denied, what happens if the patient stops responding to clinical questions, what happens if the patient wants to discontinue.
What is the platform's plan if regulatory pressure further restricts compounded GLP-1 access. The 2025 shortage resolution shifted the landscape. Continued shifts are possible. A platform that has thought about this is meaningfully different from one that hasn't.
The Patient Profiles That Actually Determine the Right Choice
If you've never been on a GLP-1 medication and you're researching options: The cheapest platform is rarely the right starting point. A more structured platform with stronger clinical follow-up — TrimRx in this comparison, or a platform outside this comparison that fits your situation — will usually serve you better during the first six months than the lowest-cost option.
If you've been on a GLP-1 before and know how you respond: The cost-focused platforms become more reasonable. Oak's pricing is genuinely competitive, and patients who already understand titration, side-effect management, and dosing can use a streamlined platform without the gaps showing up as much.
If you're switching from brand-name to compounded for cost reasons: The relevant question is whether the new platform's pharmacy partnership and clinical model match what your prescribing clinician actually wants for your case. The cheapest option may or may not be appropriate. This is a good conversation to have with your existing provider before switching.
If you have any medical complexity: Pregnancy potential, history of pancreatitis, kidney disease, mental health conditions, eating disorder history, or other complicating factors — a platform with deeper clinical engagement is usually the right choice, regardless of price differential. The cost of a complication is much higher than the savings from a cheaper platform.
Frequently Asked Questions
What is the cheapest GLP-1 telehealth platform in 2026?
Among the platforms covered here, Oak Longevity advertises the lowest entry price for compounded semaglutide at $130 per month. The cheapest platform for any specific patient depends on dose, duration, and clinical situation, not just the entry price.
Are cheap GLP-1 telehealth platforms legitimate?
Cost alone doesn't determine legitimacy. Platforms with licensed providers, licensed compounding pharmacies, transparent disclosures, and verifiable business operations are operating within an established framework. The question is which platform's clinical model fits your needs.
What's the difference between Oak Longevity, TrimRx, and MEDVi?
Oak emphasizes lowest-cost pricing and a no-video-call model. TrimRx emphasizes transparency, included follow-up care, and multiple medication form options. MEDVi emphasizes a structured medical weight loss framework with multiple medication tiers. All three operate within the compounded GLP-1 telehealth model.
Should I pick the cheapest GLP-1 platform?
Only if cost is the dominant factor in your situation and you're confident the platform's clinical model matches your needs. For most patients, the right platform is the one that balances cost with clinical engagement, not the absolute cheapest.
Is compounded GLP-1 still legal in 2026?
Yes, when prepared by a licensed 503A or 503B compounding pharmacy under proper regulatory authority. The high-volume shortage compounding era ended with the FDA shortage resolution in 2025. Compounding for documented clinical needs continues. See compounded semaglutide vs Wegovy for the full regulatory context.
What about brand-name Wegovy or Zepbound through telehealth?
Several platforms offer brand-name medications when available and clinically appropriate. The pricing is closer to retail and depends heavily on insurance coverage. For patients with good insurance coverage, brand-name through a telehealth platform may end up cheaper out-of-pocket than compounded.
The Honest Bottom Line
The cheapest GLP-1 telehealth platform in 2026 is whichever one currently has the lowest headline price at the entry titration dose. As of this writing, that's Oak Longevity at $130 per month for compounded semaglutide. That's a verifiable fact and a real cost advantage for patients paying out of pocket.
Whether the cheapest platform is the right platform for any specific patient is a different question, and the answer depends on factors that the price comparison can't capture: clinical complexity, side-effect tolerance, the depth of clinical engagement you want, and the platform's behavior when something goes wrong.
For self-directed patients with established clinical context, Oak's pricing model is genuinely competitive and worth considering. For patients newer to GLP-1 medication or with medical complexity, paying somewhat more for a platform with stronger clinical engagement usually pays off over a six-to-twelve-month treatment course.
Pick based on what fits your situation. Then verify the basics — pharmacy disclosure, provider review, side-effect protocol, refund policy — before the first order ships. That sequence holds up regardless of which platform you ultimately choose.
Leave a Reply
You must be logged in to post a comment.